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Primary objective: Beneficial effects of transcutaneous electrical nerve stimulation (TENS) on cognition
and behaviour were observed in a child with probable Herpes Simplex Encephalitis. Based on these
positive findings, it was examined in the present case study whether a child who had been diagnosed to
suffer from tuberculous meningitis would benefit from TENS. Furthermore, as aggression and over-
active behaviour were also prominent clinical symptoms, the effects of methylphenidate were inves-
tigated.
Methods and Procedures: Neuropsychological tests were used to assess attention/concentration and
visuospatial and visuoconstructive memory. Behaviour, including the level of activity during 24 hours,
was assessed by one observation scale and actigraphy.
Experimental interventions: TENS and methylphenidate.
Main outcomes and results: TENS particularly improved overall affective behaviour. Methylphenidate
appeared to have the opposite effect on cognition and hardly any effect on patient’s behaviour.
Conclusions: TENS might improve the patient’ s behavioural functioning. Pros and cons for treat-
ment effects are discussed.
Introduction
In a series of studies, patients with probable Alzheimer’s disease (AD) were treated
with Transcutaneous Electrical Nerve Stimulation (TENS) [1± 6]. The results show
that non-verbal short-term memory and non-verbal and verbal long-term (recogni-
tion) memory, as well as verbal fluency, improved by TENS. Moreover, stimulated
AD patients showed an improvement in independent functioning, affective behav-
iour, and the sleep± wake rhythm. The rationale underlying these studies was that
TENS could activate the septo-hippocampal region and the hypothalamus through
direct spinoseptal and spinohypothalamic pathways [7± 9] and, indirectly, through
the locus coeruleus (LC) and nucleus raphe dorsalis (NRD) [7± 13]. The septo-
hippocampal region and the hypothalamus play a role in long-term (recognition)
memory and affective behaviour, respectively [14± 17] and are affected in AD
[17± 19]. The deterioration in the sleep± wake rhythm is associated with neuro-
pathology in the hypothalamic nucleus suprachiasmaticus [17, 20]. In addition,
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the LC and NRD form part of the ascending reticular activating system (ARAS)
[21] which terminates, among others, in the pre-frontal cortex [22]. The pre-frontal
cortex plays an important role in response inhibition [23, 24], which might enhance
e`xecutive functions’ like attention and improve behavioural control [14, 25].
Interestingly, damage of the temporal lobe and limbic system primarily deter-
mines the clinical profile of Herpes Simplex Encephalitis (HSE) [26]. A strong
association between a deterioration in the hippocampus and a decline in memory
has been found in patients with HSE [27]. Another structure involved in HSE is the
mamillary complex of the hypothalamus [27]. Considering the overlap in affected
areas between AD and HSE and the effectiveness of TENS in AD, TENS was
applied to a 9-year-old girl who, 2 years earlier, had been diagnosed to suffer from
probable HSE [28]. The results of that study showed that TENS improved the
patient’s Verbal and Performance IQ and reduced her overactive and aggressive
behaviour.
Compared to HSE, tuberculous meningitis (TBM) produces an even more
generalized and severe neurological pattern, mostly related to hydrocephalus, fol-
lowed by infarction in preferably the right basal ganglia and in the areas innervated
often by the right middle cerebral artery [29]. More specifically, in several cases, CT
demonstrated abnormalities in the right frontal lobe, right or bilateral temporal lobes
and right or bilateral basal ganglia [30]. Considering the apparent similarities in
affected areas between AD, HSE and TBM, and encouraged by the positive effects
of TENS on cognition, independent functioning, overactive behaviour and the
sleep± wake rhythm in AD and HSE, it was hypothesized in the present study
that a 45 minute-a-day treatment with TENS could improve cognition and
aggressive and overactive behaviour in a child who suffered from TBM 18 months
earlier. Furthermore, as the patient’ s aggression and overactive behaviour were also
prominent clinical symptoms, the effects of methylphenidate, a drug mainly
prescribed to children with Attention-Deficit Hyperactivity Disorder (ADHD)
[31] were examined in the present study.
Case history
In July 1996, an 11-year-old boy became ill, with fever, dizziness and headache,
and, on suspect of meningitis, was hospitalized. After 12 days, the patient became
increasingly confused, with an intermittent level of consciousness and dysarthria. On
suspect of a viral encephalitis, acryclovir was administered. After the following 3
days, analysis of cerebrospinal fluid (CSF) appeared to be positive for TBM, and
showed a high cell count, a low glucose and a high protein concentration. Chest
radiograph showed a consolidation in the right lower lobe. Considering the pres-
ence of TBM, antituberculous therapy consisted of isoniazide, rifampicine, pyrazi-
namide, ethambutol, and dexamethason. As the tubercular bacillus appeared to be
unsensitive to INH, this drug was replaced by ciprofloxacin. The presence of
candidiasis required nystatine. About 2 weeks later, the patient showed an acute
impairment of consciousness, with a slowly reactive left pupil and hyperthermia
(>428C). On suspect of acute cerebral oedema, the patient was intubated and
hyperventilated in combination with mannitol. Computed tomography scan
(CT-scan) revealed three hypodense lesions in the right basal ganglia and the left
frontal lobe with mild surrounding oedema. A follow-up CT scan, 1 week later,
showed a reduction of the existing lesions but new lesions with oedema in the left
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basal ganglia, a new lesion in the left putamen, bilateral dilatation of the ventricles, a
widened third ventricle, and widened extracerebral spaces. Two weeks later, the
next CT scan revealed a hypodense enhancement in the left and right basal ganglia
as well as in the right internal capsule, probably consistent with infarctions. The
hypodense lesions in the left frontal lobe were suspected of an increase in encepha-
litis. EEG appeared to be asymmetrical, with focal abnormalities in the frontal areas
of the right hemisphere.
Two months after disease onset, neurological examination revealed widespread
neurological deficits, i.e., spastic tetraparesis, most pronounced at the left side,
prohibiting the patient to walk and to stand without aid. In addition, the patient
remained confused and hallucinatory at times, which could be related to the cere-
bral damage and the underlying hydrocephalus. Moreover, the psychiatrist con-
firmed an organic psychosyndrome with anxieties for which haloperidol was
advised but never taken. The patient was willing to drink and to eat only by inciting
constantly. The level of consciousness still varied, his speech was slow and dysarth-
ric, and his emotional behaviour appeared to be labile.
During the following year of rehabilitation, i.e., the period before starting the
first TENS and methylphenidate treatment, the patient’s physical condition further
improved, i.e., from the spastic tetraparesis a left hemiparesis remained. However,
particularly during walking, the left hemiparesis continued to deteriorate. The
patient began to eat and to drink more independently. Nightly restlessness occurred
frequently, for which temazepam was successfully prescribed. Of note is that the
patient’s behavioural problems remained level. When demands were placed, the
patient reacted aggressively and ran away. Furthermore, the child was overactive,
acted verbally and behaviourally aggressive and, in particular, sexually disinhibited.
By the administration of amantadine, his verbal but not his behavioural expressions
diminished. Importantly, the behavioural disturbances complicated his rehabilitation
and, instead of making progress, the patient rather deteriorated. More specifically,
the patient became more anxious, sad, and gloomy, and showed an increase in
motor restlessness. Administration of pipamperon and paroxetine appeared to
have no effect.
It is important to note that the patient’ s cognitive and behavioural functioning
showed this clinical pattern during a long period preceding the first treatment-
period with TENS, which was ¹18 months after onset of the disease.
Materials and procedure
Measurements
Considering the left hemiparesis, tests were included which appealed to functions of
the right hemisphere, i.e., visuospatial and visuoconstructive memory. In addition,
tests were administered which focused on the patient’s attention/concentration.
The disturbances in behaviour, e.g., aggression, overactivity and a depressed
mood, were evaluated by an observation scale. Patient’s rest± activity rhythm was
measured by actigraphy. The various neuropsychological tests, the observation scale
and actigraphy were applied before and after each treatment period and again after
each period without intervention.
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Neuropsychological tests
Attention/concentration
The subtests Calculation, Substitution and Digit Span from the Wechsler Intelligence Scale
for Children-Revised (WISC-R) [32] can be combined into one separate IQ factor,
called Freedom of Distractibility (FD) [33]. The subtest Calculation implies that the
children have to solve sums for which fundamental arithmetical skills are required
(e.g., subtracting) …M ˆ 10† [34]. With the subtest Substitution, the subject is asked
to associate a specific number or picture with a specific symbol …M ˆ 10† [34].
With the subtest Digit Span, the subject has to repeat a number of digits in the same
or in a reversed sequence. Besides a variety of cognitive functions, all three subtests
appeal specifically to one common cognitive function, i.e., attention/concentration
…M ˆ 10† [34].
The Bourdon-Vos [35] is a task which requires sustained attention. The test
consists of a sheet of paper with groups of dots printed on it. However, each
group has a varying number of dots, i.e., 3, 4, or 5 dots and, moreover, the dots
are differently situated in each group. The subject is asked to cross out as quickly and
accurately as possible the groups with 4 dots. Administration of the Bourdon-Vos
results in two scores: (1) the mean time in seconds per line …M ˆ 10†, and (2) the
total number of omissions …M ˆ 15† [36]. Test± retest reliability for the mean time
per line appeared to be 0.87, interrater-reliability was 0.91 [36].
Visuospatial and visuoconstructive memory
The Rey Complex Figure [37, 38]. The subject has to copy and, after a delay, draw
from memory a complex geometrical figure. Copying the figure requires planning
and strategy whereas, in the second part, the test appeals to the subject’s visual
memory [39]. Scoring: to each separate element of the figure points are attached,
with a maximum score of 36. Internal consistency (Cronbach’s ¬) for the subtest
Copy was 0.60 and for the Delayed Reproduction from memory 0.82 [39].
The Benton Visual Retention Test, version A [40]. This test includes 10 pictures,
each picture consisting of one or more abstract figures. Version A implies that each
picture is presented to the subject during 10 seconds; directly after the presentation,
the subject must draw the picture from memory. Scoring: 1 point for a correct
reproduction, whereas an inappropriate reproduction, irrespective of type of error,
receives no points (maximum score: 10). The highest interrater-reliability for
Number Correct was 0.96 and for Error scores 0.97 [41]. Test± retest reliability
coefficients were reported at 0.57 for Number Correct and 0.53 for Error scores
[41].
The Raven Progressive Matrices [42]. This test appeals to the subject’s reasoning by
analogy and abstract thinking [39]. A booklet is presented to the subject, each page
containing an abstract pattern with one part left out. At the bottom of the page,
several bits are printed with various patterns and only one bit is the right one to
complete the pattern of the upper figure. Scoring: the total number of correct
answers (maximum score: 60). The reliability coefficient by means of Cronbach’s
¬ ( i`nternal consistency’) appeared to be 0.90 [41].
Observation scale
The Revised Conners Parent and Teacher Rating Scale [43] was used to rate the various
behavioural symptoms and to evaluate possible treatment effects. The scale includes
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seven subscales, i.e., conduct problem I (max score: 30), learning problem (max
score: 12), psychosomatic (max score: 15), impulsive-hyperactive (max score: 12),
conduct problem II (max score: 9), anxiety (max score: 12), and other items (max
score: 54). A lowering of the score implies an improvement in behaviour.
Actigraphy
The rest± activity rhythm was assessed using actigraphy [6] on several occasions, i.e.
before and after each treatment (free) period. On each occasion, the patient wore an
actigraph around the right, non-paretic wrist, for an average of 7 days. From the
resulting rest± activity rhythms, several non-parametric variables can be calculated, as
described in detail previously [6]. For the purpose of the present study, two variables
were of importance, i.e., (1) L5, which represents the subject’ s five least active
hours, and (2) M10, which includes 10 hours of the subject’s maximum activity,
both within 24 hours.
Intervention
The patient was treated either with TENS or with methylphenidate.
TENS
Frequency and intensity. The patient was treated with an electro-stimulator, type
Premier 10s. This stimulator generates transcutaneous electro-stimulation which
consists of asymmetric biphasic square impulses, applied in bursts of trains, nine
pulses per train, with an internal frequency of 160Hz, a repetition rate of 2Hz,
and a pulse width of 100 mseconds. This type of TENS is known as BURST-TENS
[44]. The intensity of the stimulation triggered visible muscular twitches, which
were painless. A flickering green light placed on the electro-stimulator indicated
stimulation.
Location. Two 2£ 3 cm …h£ w† self-adhesive carbon rubber electrodes were
fixed on the patient’ s back between Th1 and Th5, each on one side of the spinal
column.
Duration. The patient was offered a stimulation time of 45 minutes per day,
between 16:00 and 19.00 h, for 7 days a week, during a period of ¹3 months.
Methylphenidate
The patient took methylphenidate three times a day, i.e., 8 am, around 12 and at
4 pm. To determine the most optimal treatment, methylphenidate was first admin-
istered at a low dose, which was raised in the following way. During the first week,
the patient took 5 milligrams of methylphenidate at each point of time. The next
week, the patient took a tablet of 10 milligrams at 8 am and around 12, and a tablet
of 5 milligrams at 4 pm. This procedure was maintained during the third week,
whereas in the fourth week the dose was raised up to 15 milligrams (one and a half
tablets) for the medication at 8 am and around 12, whereas the medication at 4 pm
remained level (5 milligrams). These different dosages were maintained during the
following 2 months of treatment.
During the total treatment period of 3 months, blood pressure, pulse, and body
weight were frequently checked, i.e., during the first month, once a week and,
subsequently, once a month.
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Amantadine
The patient took amantadine since the onset of the disease. Amantadine was admin-
istered to enhance, among others, attention/concentration, arousal, processing time
and psychomotor speed and to reduce agitation and anxiety [45]. However, to
exclude possible side-effects, e.g., confusion and nightmares [46] which might be
mixed up with the other clinical symptoms, it was decided to stop the administra-
tion of amantadine (Delay2; table 1).
Design
First, the patient was treated by TENS during 3 months (Post1), followed by a
treatment-free period of 2 months (Delay1). At that moment, the administration of
amantadine was stopped and the patient was tested again 2 months later (Delay2).
Because of the summer holidays, the patient was tested again 2 months later, just
before methylphenidate was administered (Delay3ˆ Pre2). The possible effects of
methylphenidate were evaluated 3 months later (Post2), followed by a treatment-
free period of 2 months, after which the patient was tested again (Delay4ˆPre3).
At that moment, TENS was applied again for 3 months (Post3), followed by a
treatment-free period of 6 weeks (Delay5). The various treatment (free)-periods are
presented in figure 1.
Data-presentation
The results of the various neuropsychological tests and Conners Scale are presented
in table 1, with mean (standard) scores and maximum scores.
For each of the two variables, i.e., L5 and M10, describing the rest-activity
rhythm, two-tailed paired t-tests at a 0.05 significance level were performed on
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Table 1. Mean standard scores
a
; mean scores
b
; maximum scores
c
. A’dineˆAmantadine; WISC-R: Wechsler
Intelligence Scale for Children, Revised. Freedom of Distract.: Freedom of Distraction. Methyl: methylphenidate
Mean‡ Pre1 Post1 Delay2 Delay3= Post2 Delay4ˆ Post3
Max. start stop no Pre2 start stop Pre3 start stop
score TENS TENS Delay1 A’dine methyl methyl TENS TENS Delay5
Tests
WISC-R
Freed. of Distract. 100
a
84 90 88 84 99 77 66 86 88
Calculation 10
a
9 10 10 8 11 4 6 11 10
Substitution 10
a
1 2 3 1 5 2 2 1 1
Digit Span 10
a
12 14 12 13 14 14 12 12 14
Bourdon-Vos
Seconds per line 10
b
40.3 26 28.9 34.4 26.4 26.9 28.9 27.18 21.09
Omissions 15
b
34 29 2 2 2 5 7 3 3
Rey Figure
Copy 36
c
26.5 32 33 33 36 29 32 30 36
Memory 36
c
15 18 21 24 22 23 19 23.5 26
Benton A version 10
c
Hits 5 6 2 5 7 5 7 5 5
Failures 5 4 8 5 3 5 3 5 5
Raven matrices 60
c
Hits 35 39 39 40 38 31 37 35 44
Failures 25 21 21 20 22 29 23 25 16
Conners Scale
Totalscore 144
c
45 18 16 25 23 21 28 14 18
two orthogonal contrasts [47]; baseline 1 versus baseline 2 and experimental versus
pooled baseline. Baseline levels were pooled in order to reduce the repeated meas-
urement within-subject variability. The use of this procedure is appropriate when a
lack of difference between two levels (baseline 1 and 2) can be demonstrated. If t-
tests indicated no differences between baseline 1 and 2, F statistics on the contrast of
the experimental versus pooled baseline levels are justified. If baseline 1 and 2 differ
significantly, F statistics should be performed on the contrast of baseline 1 versus
experimental baseline, and experimental baseline versus baseline 2. The results of
the actigraphy are presented in figure 2.
Results and discussion
The results will be presented and discussed per separate treatment(free) period.
Pre1± Post1± Delay 1 ( first TENS treatment)
After the first treatment period with TENS, the patient showed higher scores on the
WISC-R/FD, the Bourdon-Vos, the Rey Complex Figure, the Benton Visual
Retention Test and the Raven Progressive Matrices. These cognitive improvements
coincided with an improvement in overall behaviour (lower score on the Conners
Scale).
After the first treatment-free period, the scores on the WISC-R/FD slightly
decreased. It should be noted, however, that, although speed of processing of the
Bourdon-Vos slowed down somewhat, the number of omissions with the
Bourdon-Vos decreased remarkably. Patient’s performance on the visuospatial
and visuoconstructive memory tests showed conflicting results. The score on the
Benton Visual Retention Test declined, on the Raven Progressive Matrices
remained level and on the subtest Memory of the Rey Complex Figure further
improved. In addition, the score on the Conners Scale lowered just a little.
As for the actigraphy variables L5 and M10, t-tests indicated no differences
between baseline 1 and 2. Consequently, F-statistic on the contrast of the
experimental versus pooled baseline levels was performed, which showed that
M10 directly following TENS treatment (mean§ SD) (32 415:75§ 1516:43†
was significantly decreased …p ˆ 0:001† over-pooled baseline values
…49 749:25§ 2069:60†, whereas L5 directly following TENS …970 § 101:34† did
not significantly decrease …p ˆ 0:23† over-pooled baseline values
…1083:12§ 52:25†.
The improvements in the neuropsychological tests and the Conners Scale after
the treatment period, the decline and stability in the majority of the tests and
Conners Scale after the treatment free period, together with the significant effect
on the M10 rest± activity variable support a real treatment effect of TENS.
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Figure 1. The various treatment(free) periods. Methyl: methylphenidate; aman: amantadine.
Delay 1± Delay 2± Delay 3 (period without amantadine)
After the next period, in which the patient stopped taking amantadine, patient’s
performance on the WISC-R/FD and speed of processing of the Bourdon-Vos
further declined. In contrast, the scores on the Memory subtest of the Rey Figure,
the Benton and the Raven Matrices showed some improvement. Importantly, the
patient’s behaviour deteriorated during this period (higher score on the Conners
Scale).
After the next treatment-free period, up to the start of methylphenidate, the
patient showed enhanced scores on all tests, except for the scores on the subtest
Memory of the Rey Complex Figure and the Raven Progressive Matrices which
hardly declined. Also, the patient’s behaviour (Conners Scale) improved slightly.
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Figure 2. Scores on the actigraphy variables L5 and M10 (nightly restlessness and activity by day, respectively) at
various moments of measurement. Aman: amantadine; methyl: methylphenidate; del: delayed measurement.
As for the actigraphy variables L5 and M10, t-tests indicated significant differ-
ences between baseline 1 and 2. Therefore, for both variables, F statistic was
performed on the contrast of baseline 1 versus experimental baseline and experi-
mental baseline versus baseline 2. The results show that M10 directly following the
period without amantadine …24 677:50§ 1443:45† significantly decreased
…p ˆ 0:03† over baseline 1 …42 213:75§ 5302:67†, but did not significantly increase
…p ˆ 0:14† over baseline 2 …28 792:25 § 2005:06†. Similar results were observed for
L5, i.e. L5 directly following the period without amantadine …223§ 21:14† sig-
nificantly decreased …p ˆ 0:003† over baseline 1 …976 § 114:64†, but showed no
significant increase …p ˆ 0:43† over baseline 2 …236:25§ 47:37†.
These results are consistent with expectations. Amantadine is prescribed to
enhance attention/concentration and psychomotor speed and to reduce agitation
and anxiety [45]. Consequently, cessation of amantadine should produce the oppo-
site pattern, which indeed was observed, i.e., a decrease in attention/concentration
and an increase in behavioural disturbances. Moreover, confusion and nightmares
are known side-effects of amantadine [46]. Of note is that L5 and M10 showed
lower values after the taking of amantadine had stopped. These findings strengthen
the reliability of the applied measurements and weaken the possible influence of
test± retest effects.
Delay 3± Post2± Delay 4 (methylphenidate treatment)
Unexpectedly, after the treatment with methylphenidate, the scores on the WISC-
R/FD, the subtest Omissions of the Bourdon-Vos, the subtest Copy of the Rey
Figure, the Benton and the Raven Matrices declined. Only the performance on the
subtest Memory of the Rey Figure slightly improved. In addition, the score on the
Conners Scale decreased. Such an adverse effect of methylphenidate on cognition
has, as far as the authors know, only been observed when it was combined with
imipramine [48].
In the treatment-free period, the performance on the WISC-R/FD and the
Bourdon-Vos further decreased. In contrast, the performance on all other testsÐ
except for the subtest Memory of the Rey Complex FigureÐ recovered.
Furthermore, the patient’s overall behaviour deteriorated again.
Only for the actigraphy variable M10, t-tests indicated no differences between
baseline 1 and 2. Consequently, the F-statistic on the contrast of the experimental
versus pooled baseline levels was performed, which showed that M10 directly
following methylphenidate …40 899:50§ 1203:21† significantly increased
…p ˆ 0:009† over pooled baseline values …31 744:25§ 973:97†. For L5, the F-sta-
tistic was performed on the contrast of baseline 1 versus experimental baseline and
experimental baseline versus baseline 2. The results show that L5 directly following
methylphenidate …1252:50 § 58:67† significantly increased …p ˆ 0:0005† over base-
line 1 …236:25§ 47:37†, but did not significantly decrease …p ˆ 0:10† over baseline
2 …890:00§ 225:20†. The increase in nightly restlessness, measured by actigraphy, is
a more common adverse effect of methylphenidate [31]. Importantly, this latter
finding supports the reliability of the actigraphy-registration in the present case
study.
The varying performance on the neuropsychological tests and the increase in
behavioural disturbances are not easy to interpret. One plausible reason might be
that in this period the patient was told that his schoolteacher, who was a great
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support for him during his illness and in whom he had a lot of confident, would
leave the school. Possibly, the forthcoming departure of the schoolteacher might
have influenced the patient’s cognitive and behavioural functioning. Considering
the effect of methylphenidate on L5 and M10 in the former period, a decrease in
both rest± activity variables was expected to occur after cessation of methylpheni-
date.
Pre3± Post3± Delay 5 (second TENS treatment)
After this second treatment with TENS, the scores on the WISC-R/FD and the
Bourdon-Vos improved considerably. However, the performance on the majority
of the visuospatial and visuoconstructive memory tests declined somewhat, i.e., only
the performance on the subtest Memory of the Rey Complex Figure enhanced.
Another remarkable improvement was observed in the patient’ s overall behaviour
(Conners Scale).
After the treatment-free period, the data show that not only the patient’s per-
formance on the WISC-R/FD and the speed of processing of the Bourdon-Vos
further improved, but also that the performance on the Rey Figure and Raven
Matrices, which declined somewhat in the former period, was better. However,
after stopping TENS, a decline in the patient’s performance on the various tests was
expected. Only patient’s behaviour worsened (Conners Scale) after the treatment-
free period.
As for the actigraphy variables L5 and M10, t-tests indicated significant differ-
ences between baseline 1 and 2. Therefore, for both variables, the F-statistic was
performed on the contrast of baseline 1 versus experimental baseline and experi-
mental baseline versus baseline 2. The results show that M10 directly following
TENS …38 200:50§ 3098:21† did not significantly increase …p ˆ 0:20† over base-
line 1 …34 696:25 § 2510† and did not significantly decrease …p ˆ 0:08† over base-
line 2 …32 246:50 § 3730:12†. Similar results were observed for L5, i.e. L5 directly
following the period with TENS …799§ 119:92† did not significantly change
…p ˆ 0:41† over baseline 1 …890 § 225:20†, and over baseline 2 …757:75§ 58:34†
…p ˆ 0:40†.
In sum, the majority of these findings could be considered as a con for real
treatment effects of TENS. On the other hand, the patient does not suffer from a
progressive disease, and it might be just as realistic to expect a prolonged effect after
a second application of a particular type of stimulation. In other words, one could
speculate that after a period of 3 months with TENS, certain brain areas may
continue to show improved functioning and, possibly, may also exert a beneficial
influence on other brain areas.
Conclusions and limitations
TENS
On the basis of the results of each separate treatment(free) period, it is hard to make
firm conclusions about the influence of TENS on patient’s cognitive functioning.
Although the enhanced performance on the Bourdon-Vos after TENS might sug-
gest improved attention/concentration, this finding is not supported by the scores
on the WISC-R/FD. Indeed, the subtests of the FD were included in the present
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study specifically to evaluate attention/concentration. However, attention/
concentration can be measured by the FD only under the condition that its three
subtests will obtain about the same mean. This appeared not to be the case in the
present study. During all treatment(free) periods, Digit Span remained well above
the average level, whereas only very low scores were observed for Substitution. In
other words, in the present study the WISC-R/FD may not be considered as a
reliable measure for attention and concentration.
It is noteworthy, though, that the patient’s behavioural functioning (Conners
Scale) improved considerably after each TENS-application and declined or
remained level after cessation of TENS. Only these latter findings support the
hypothesis on the effects of TENS in TBM.
Cessation of amantadine and administration of methylphenidate
The most constant pattern in clinical symptoms was observed after the patient
stopped taking amantadine and after administration of methylphenidate. The
clinical profile which resulted after cessation of amantadine met the expectations
and matched perfectly the outcome of the selected measurements, i.e. the
neuropsychological tests, the Conners Scale and the actigraphy. The effects of
methylphenidate were not anticipated, but the clinical findings appeared to be all
in the same direction.
Overall evaluation
So far, the results of each separate treatment (free) period, with and without aman-
tadine, were reviewed. Obviously, during these periods all kinds of transient posi-
tive and negative influences which could not be prevented might have played a role.
Therefore, irrespective of type of intervention, it would also be worthwhile to
evaluate the level of patient’ s cognitive and behavioural functioning over the
whole period from Pre1 (start TENS) up to Delay 5, a period which took up 1.5
years. The data in table 1 suggest that, except for the scores on the Benton Visual
Retention Test which did not change, patient’s performance on all neuropsycho-
logical tests improved. Moreover, patient’s overall behaviour enhanced dramatically
(Conners Scale) as well as nightly restlessness (L5) and overactivity by day (M10)
(figure 2). Of course, these improvements could be the result of n`atural’ recovery
processes, but it is emphasized that there was no such recoveryÐ rather a declineÐ
during a long period preceding the first TENS-treatment (Pre1± Post1).
Limitations
The present study also has some specific caveats. In the first place, the study coin-
cided with the construction of an extensive medical team which provided, among
other things, a strong social support for the patient and his mother. These social
changes might have positively influenced the effects of TENS, but the question why
methylphenidate was counterproductive remains unanswered. Moreover, TENS
was applied by the parent at home under normal circumstances, i.e., in the absence
of the investigator who could have been viewed as an additional source of stimula-
tion. In the second place, in a study with multiple measurements, test± retest effects
do play a role. On the other hand, during the 18 months of treatment in the present
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study, the patient showed lower scores on the majority of the tests at several
occasions, i.e., after the first treatment-free period (Delay1), after the period without
amantadine (Delay2), and after methylphenidate (Post2). More specifically, com-
pared to the cognitive scores after TENS-treatment (Post1), the patient performed
worse on the majority of the tests after methylphenidate (Post2), whereas all tests
were administered again three times following Post1. In the third place, the results
of the present study do not provide direct evidence that the pre-frontal cortex, the
septo-hippocampal region, and the hypothalamus are indeed activated by TENS.
Finally, although the present results should be considered with great caution,
they are challenging enough to warrant further research.
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